1. Scrip
  2. >>Business

Clasp Launches With $150m To Develop Personalized T-Cell Engagers

Dual Agents Target Oncogenes And HLA Proteins

 
• By Mandy Jackson

Clasp Therapeutics, which emerged from labs at Johns Hopkins University and was incubated by a pair of venture capital investors, plans to achieve a clinical trial readout with its series A cash.

Start-up Funding Crowdfunding Investment Venture Capital Entrepreneurship Internet Business Technology Concept
Clasp will take at least one candidate into the clinic with its new funding • Source: Shutterstock

Clasp Therapeutics is developing next-generation T-cell engagers with the aim of developing off-the-shelf immuno-oncology therapeutics that have precise tumor targeting with limited on-target, off-tumor adverse events. And now with a $150m series A venture capital round announced on 20 March, the company plans to develop its first therapeutic candidates from preclinical all the way through initial clinical trial data.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform

 
• By Jung Won Shin, Lisa Takagi, Joseph Haas, Anju Ghangurde, and Vibha Ravi

Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.

Cancer Retains Top Spots In Alliance Deal Volume, Value

 
• By Joseph Haas

Cancer assets drove the highest percentage of biopharma alliance dealmaking in 2024, tripling the frequency of the next highest therapeutic category, neurology.

Oncology’s Most Eligible Unpartnered Assets

 
• By Edwin Elmhirst

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.